سعر افيبيرافير 200مجم 40 قرص 2025

Favipiravir 200 mg film-coated tablets, 40 tablets (4 strips); antiviral RNA-dependent RNA polymerase inhibitor (Eva Pharma, Egypt).

• Novel or re-emerging pandemic influenza virus infections, limited to cases in which other anti-influenza virus agents are ineffective or insufficiently effective; use only when the government decides to use it.Population: AdultsBfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• Most frequent in Japanese clinical studies: blood uric acid increased (4.79%), diarrhoea (4.79%), neutrophil count decreased (1.80%), AST increased (1.80%) and ALT increased (1.60%).International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• Clinically significant adverse reactions (reported with favipiravir or similar anti-influenza agents): shock/anaphylaxis, pneumonia, fulminant hepatitis/hepatic dysfunction/jaundice, toxic epidermal necrolysis and Stevens-Johnson syndrome, acute kidney injury, decreased white blood cells/neutrophils/platelets, neurological and psychiatric symptoms, and haemorrhagic colitis.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• Women known or suspected to be pregnant.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• History of hypersensitivity to any ingredient of the product.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• Warning (boxed in the Japanese label): early embryonic death and teratogenicity in animals: do not administer to women known or suspected to be pregnant; confirm a negative pregnancy test before starting in women of child-bearing potential and ensure the most effective contraception during and for 7 days after treatment; the drug is distributed in sperm, so men must use contraception (condom) and avoid intercourse with pregnant women; explain risks thoroughly and obtain consent.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• Use with care in patients with gout or a history of gout and in hyperuricaemia: blood uric acid may increase and symptoms may be aggravated.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• Abnormal behaviour (e.g. sudden running, wandering) has been reported in influenza patients regardless of treatment, particularly children and adolescents; patients should not be left alone for at least 2 days after the start of treatment.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• PyrazinamideBlood uric acid levels increase (additive effect on renal tubular uric acid reabsorption).BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• RepaglinideBlood repaglinide levels may increase through CYP2C8 inhibition by favipiravir.BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• TheophyllineBlood favipiravir levels may increase (theophylline interaction with xanthine oxidase).BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• Contraindicated in women known or suspected to be pregnant: early embryonic death and teratogenicity were observed in animal studies.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)
• Breastfeeding must be discontinued during treatment; the hydroxylated metabolite of favipiravir was found in human breast milk.International label, same formulation · BfArM-hosted English translation of the Japanese prescribing information (FUJIFILM Toyama Chemical)

• Favipiravir: Metabolised in cells to its ribosyl triphosphate form (favipiravir RTP), which selectively inhibits the RNA polymerase involved in influenza viral replication; little inhibitory effect on human DNA polymerases alpha, beta and gamma.